EX-99.1

2 d113773dex991.htm

EX-99.1

EX-99.1

Exhibit 99.1

Lumexa Imaging Announces Second Quarter 2026 Results

RALEIGH, N. C., August 12, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated its full year 2026 outlook.

“During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Some highlights include announcing four new imaging centers year to date and a joint venture with Hospital for Special Surgery (HSS), a globally recognized leader in musculoskeletal health, marking our ninth health system partnership and our second new joint venture in the past twelve months.”

“With a large and growing addressable market and durable demand tailwinds, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.”

Second Quarter 2026 Highlights:

All comparisons are to the quarter ended June 30, 2025, unless otherwise noted

•

Consolidated revenues of $264.2 million, an increase of 5.1% from $251.4 million

•

System-wide revenue growth of 6.0%

•

Consolidated advanced outpatient volume growth of 6.8% and 6.3% system-wide

•

Same-center advanced outpatient volume growth of 5.2% consolidated and 4.9% system-wide

•

Net income of $2.7 million as compared to net loss of $7.2 million

•

Adjusted EBITDA of $56.4 million as compared to $56.3 million; and a 21.4% Adjusted EBITDA margin as compared to 22.4%

•

GAAP EPS of $0.03 per share and Adjusted EPS of $0.20 per share

2026 Full Year Outlook:

Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.

•

Reiterating full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion.

•

Narrowing its full-year 2026 Adjusted EBITDA guidance range to $235 million to $241 million, from its

prior range of $234 million to $242 million. The midpoint of $238 million is unchanged. This includes approximately $7 million of public company costs that were not incurred in 2025. (At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%)

•

Reiterating guidance for Adjusted EPS of $0.71 to $0.77 per share.

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its second quarter 2026 results, as well as its 2026 outlook, on August 12, 2026 at 5:00 p.m. ET. The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of Non-GAAP Financial Measures

This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance; (ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and greater than 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,

EX-99.1

2 d138307dex991.htm

EX-99.1

EX-99.1

Exhibit 99.1

Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance

RALEIGH, NORTH CAROLINA, March 26, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced certain financial results for the fourth quarter ended December 31, 2025, and reiterated full year 2026 guidance. The financial results included in this release pertaining to the fourth quarter and full year 2025 are preliminary, unaudited, and subject to final review and adjustment.

“The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Strong Adjusted EBITDA growth was driven by advanced imaging volumes, ramping new de novo centers, and our return in-network with a large payer in New Jersey. We strengthened our balance sheet, reducing leverage by two turns, and opened a record number of de novo centers during the year, setting the stage for future growth.”

Ms. Zulla continued, “Looking ahead, our 2026 outlook reflects continued growth and margin expansion, supported by durable demand tailwinds and the ongoing shift to outpatient care. With a focused strategy centered on same-center growth, geographic expansion, and advanced imaging, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.”

Fourth Quarter 2025 Highlights:

All comparisons are to the quarter ended December 31, 2024, unless otherwise noted

•

Consolidated revenues of $267.7 million, an increase of 7.9% from $248.0 million

•

System-wide revenue growth of 10.6%

•

Same center advanced volume growth: 12.7% for consolidated and 9.2% for system-wide

•

Net loss of $28.7 million compared to $25.1 million

•

Adjusted EBITDA of $63.8 million, an increase of 18.6% from $53.7 million; and a 23.8% Adjusted EBITDA margin

•

Achieved a two-turn reduction in leverage from 5.5 times to 3.5 times, resulting in more than $50 million in

annual cash savings

2025 Full Year Highlights:

All comparisons are to the year ended December 31, 2024, unless otherwise noted

•

Added ten new imaging facilities: Nine de novo centers (six wholly owned and three through joint ventures) and one acquired site

•

Consolidated revenues of $1.023 billion, an increase of 7.8% from $948.9 million

•

System-wide revenue growth of 8.2%

•

Same center advanced volume growth: 8.0% for consolidated and 7.1% for system-wide

•

Net loss of $47.1 million compared to $94.1 million

•

Adjusted EBITDA of $230.2 million, an increase of 14.6% from $200.8 million; and a 22.5% Adjusted EBITDA margin

Outpatient Volumes:

Consolidated

2025

2024

Increase YoY

4Q25

4Q24

Increase YoY

Consolidated total procedures

2,418,096

2,312,645

4.6 %

627,293

569,734

10.1 %

Consolidated advanced procedures

728,304

675,697

7.8 %

190,982

167,184

14.2 %

% advanced procedures

30.1 %

29.2 %

90bps

30.4 %

29.3 %

110bps

Consolidated same-center advanced volume growth

—

—

8.0 %

—

—

12.7 %

System-wide

System-wide total procedures

3,972,228

3,840,624

3.4 %

1,027,590

962,520

6.8 %

System-wide advanced procedures

1,444,618

1,340,951

7.7 %

379,527

341,859

11.0 %

% advanced procedures

36.4 %

34.9 %

145bps

36.9 %

35.5 %

142bps

System-wide same-center advanced volume growth

—

—

7.1 %

—

—

9.2 %

Note: Advanced Procedures includes MRI and CT modalities

2026 Full Year Outlook:

The company is reiterating its outlook for the year ending December 31, 2026. Lumexa Imaging continues to expect:

•

Consolidated revenues of $1.045 to $1.097 billion

•

Adjusted EBITDA of $234 to $242 million. This includes approximately $7 million of public company costs that were not incurred in 2025. (At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%.)

The company is also providing guidance for Adjusted EPS of $0.71 to $0.77 per share

The financial information above is preliminary and subject to Lumexa Imaging’s normal quarter and year-end accounting procedures and external audit by Lumexa Imaging’s independent registered public accounting firm. In addition, these preliminary unaudited results are not a comprehensive statement of Lumexa Imaging’s financial results for the year ended December 31, 2025, should not be viewed as a substitute for full, audited consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), and are not necessarily indicative of Lumexa Imaging’s results for any future period.

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its fourth quarter and full year 20